Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders
A Randomized Clinical Trial Comparing Cumulative Live Birth Rates in Dual Ovarian Stimulation Versus Two Antagonist Stimulations in Poor Ovarian Responders
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women with POR were defined with adjusted Bologna criteria, at least two of the three following criteria: advanced maternal age (40 years); 3 oocytes in previous IVF; and antral follicle count (AFC) 5 and/or anti-Mu¨llerian hormone (AMH) 1.1 ng/ml (this criterion was mandatory)
- Aged from 20 to 44 years
- Body mass index (BMI) from 19 to 32 kg/m2
- No more than two previous IVF cycles were recruited
Exclusion Criteria:
- Amenorrhoea
- Follicle stimulating hormone (FSH) 20 IU/L or AFC 1
- Women with a partner with an extremely severe sperm anomaly or sperm donor use
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dual Stimulation Protocol
Dual stimulations were performed during the follicular and luteal phases in the same cycle.
|
Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group.
In the duostim group, all of the embryos are frozen.
Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
|
|
Active Comparator: Antagonist Stimulation Protocol
Antagonist stimulations were performed during two consecutive follicular phases in two cycles.
|
Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group.
In the duostim group, all of the embryos are frozen.
Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cumulative live birth rate
Time Frame: 36 months
|
Live birth is defined as the delivery of any alive infant after 22 weeks of gestation after our interventions, and cumulative live birth rate is calculated by the total number of women randomized to the specific group.
|
36 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical pregnancy rate
Time Frame: 36 months
|
Twenty days after conception, transvaginal ultrasonography will be performed.
Clinical pregnancy will be diagnosed with detection of an intrauterine gestational sac.
|
36 months
|
|
Time to live birth (TTLB)
Time Frame: 36 months
|
The TTLB was measured as the time from ovarian stimulation to a live birth.
|
36 months
|
|
Total amount of Gn used during ovarian stimulation
Time Frame: 24 months
|
Total amount of Gn used during ovarian stimulation
|
24 months
|
|
Number of retrieved oocytes
Time Frame: 24 months
|
Number of retrieved oocytes after ovarian stimulation.
|
24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- shanghaiFMIH-20231006
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.